Skip to main content

Advertisement

SpringerLink
Log in

The role of adjuvant immunotherapy in renal cell carcinoma

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

After nephrectomy for renal cell carcinoma (RCC), a significant number of patients develop recurrent disease. In order to improve the prognosis of these patients, the role of adjuvant immunotherapy should be clarified; the appropriate selection of patients is especially crucial. For this purpose, the search for prognostic factors is important to identify at-risk patients. Known factors such as stage, grade, and microvascular invasion can be used for appropriate selection. Other molecular markers, such as cadherin-6 and G250 antigen, may become important. So far, adjuvant immunotherapy in RCC has not shown improved survival data, but the results may be hampered by inadequate recruitment and follow-up. Adequate selection of patients and the search for less toxic and more effective immunotherapy approaches are of importance. Therefore, the use of monoclonal antibody G250 or dendritic cell vaccinations, alone or together with cytokines, may be advantageous and is currently used. Today, adjuvant protocols are open for recruitment of patients to elucidate the important question as to whether this approach should be implemented in the treatment of RCC. In this article, an update is given in the field of adjuvant immunotherapy in patients with RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Garnick MB, Richie JP: Renal neoplasia. In The Kidney. Edited by Brenner BM, Rector FC Jr. Philadelphia: WB Saunders Co.; 1991:1809–1827.

    Google Scholar 

  2. Parker SL, Tong T, Bolden S et al.: Cancer statistics, 1997. CA Cancer J Clin 1997, 47:5–27.

    PubMed  CAS  Google Scholar 

  3. Katz DL, Zheng T, Holford TR, et al.: Time trends in the incidence of renal carcinoma: analysis of Connecticut Tumor Registry data, 1935–1989. Int J Cancer 1994, 58:57–63.

    Article  PubMed  CAS  Google Scholar 

  4. McDougal WS, Garnick MB: Clinical signs and symptoms of renal cell carcinoma. In Comprehensive Textbook of Genitourinary Oncology. Edited by Vogelzang NJ, Scardino PT, Shipley WU, et al. Baltimore: Williams & Wilkins 1996:154–159.

    Google Scholar 

  5. Waters WB, Richie JP: Aggressive surgical approach to renal cell carcinoma: review of 130 cases. J Urol 1979, 122:306–309.

    PubMed  CAS  Google Scholar 

  6. Golimbu M, Joshi P, Sperber A, et al.: Renal cell carcinoma: survival and prognostic factors. Urology 1986, 27:291–301.

    Article  PubMed  CAS  Google Scholar 

  7. Kozlowski JM: Surgical resection of metastatic disease. In Comprehensive Textbook of Genitourinary Oncology. Edited by Vogelzang NJ, Scardino PT, Shipley WU, et al. Baltimore: Williams & Wilkins 1996:284–292.

    Google Scholar 

  8. Sigel A, Chlepas S., Schrott KM, Hermanek P: Surgery of the kidney tumor [in German]. Surgeon 1981, 52:545–553.

    CAS  Google Scholar 

  9. Pizzocaro G, Piva L: Pros and cons of retroperitoneal lymphadenectomy in operable renal cell carcinoma. Eur Urol 1990, 18(suppl 2):22–23.

    PubMed  Google Scholar 

  10. Porzsolt F: Adjuvant therapy of renal cell cancer with interferon-alpha 2a. Delta-p gruppe. Proc Am Soc Clin Oncol 1992, 11:202.

    Google Scholar 

  11. Herrlinger A, Schrott KM, Schott G, Sigel A: What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 1991, 146:1224–1227.

    PubMed  CAS  Google Scholar 

  12. Blom JH, van Poppel H, Marechal JM, et al.: Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 1999, 36:570–575.

    Article  PubMed  CAS  Google Scholar 

  13. Zisman A, Pantuck AJ, Dorey F, et al.: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649–1657. This article refocuses our interest in the prognostic factor analysis of RCC. It may help in appropriate selection of patients for adjuvant protocols.

    PubMed  CAS  Google Scholar 

  14. Van Poppel H, Vandendriessche H, Boel K, et al.: Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. J Urol 1997, 158:45–49. This article is an example of the detection of a new and independent prognostic factor. Microvascular invasion became an inclusion criteria for at-risk patients for recurrent disease after tumor nephrectomy in the European Organization for Research and Treatment of Cancer adjuvant protocol.

    Article  PubMed  Google Scholar 

  15. Katagiri A, Watanabe R, Tomita Y: E-cadherin expression in renal cell cancer and its significance in metastasis and survival. Br J Cancer 1995, 71:376–379.

    PubMed  CAS  Google Scholar 

  16. Nouwen EJ, Dauwe S, van der Biest I, De Broe ME: Stage- and segment-specific expression of cell-adhesion molecules N-CAM, A-CAM, and L-CAM in the kidney. Kidney Int 1993, 44:147–158.

    Article  PubMed  CAS  Google Scholar 

  17. Shimazui T, Oosterwijk E, Debruyne FM, Schalken JA: Molecular prognostic factor in renal cell carcinoma. Semin Urol Oncol 1996, 14:250–255.

    PubMed  CAS  Google Scholar 

  18. Grabmaier K, Vissers JL, De Weijert MC, et al.: Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000, 85:865–870.

    Article  PubMed  CAS  Google Scholar 

  19. Murakami Y, Kanda K, Tsuji M, et al.: MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 1999, 83:743–747.

    Article  PubMed  CAS  Google Scholar 

  20. Yagoda A, Petrylak D, Thompson S: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993, 20:303–321.

    PubMed  CAS  Google Scholar 

  21. Heinzer H, Huland E, Huland H: Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol 2001, 19:111–119.

    Article  PubMed  CAS  Google Scholar 

  22. Mulders P, Figlin R, deKernion JB, et al.: Renal cell carcinoma: recent progress and future directions. Cancer Res 1997, 57:5189–5195. This article gives an overview on the current status of more specific immuno-and gene therapy approaches in RCC treatment. It implements translational research projects in this field.

    PubMed  CAS  Google Scholar 

  23. Atzpodien J, Kirchner H, Hanninen EL, et al.: European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol 1993, 20(suppl 9):22–26.

    PubMed  CAS  Google Scholar 

  24. van Herpen CM, Jansen RL, Kruit WH, et al.: Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 2000, 82:772–776.

    Article  PubMed  Google Scholar 

  25. Motzer RJ, Murphy BA, Bacik J, et al.: Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 18:2972–2980.

    PubMed  CAS  Google Scholar 

  26. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ: Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 1998, 16:1820–1825.

    PubMed  CAS  Google Scholar 

  27. Pizzocaro G, Piva L, Colavita M, et al.: Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001, 19:425–431. This article describes one of the few protocols in adjuvant treatment of RCC. It includes the problems of adequate selection and follow-up of this patient category. Also, the toxicity of immunotherapy with dose reduction becomes clear.

    PubMed  CAS  Google Scholar 

  28. Trump DL, Elson P, Propert K et al.: Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon in resected, high risk renal cell carcinoma: an ECOG study [abstract 648]. Proc Am Soc Clin Oncol 1996, 15:253.

    Google Scholar 

  29. Mule JJ, Ettinghausen SE, Spiess PJ et al.: Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res 1986, 46:676–683.

    PubMed  CAS  Google Scholar 

  30. Debruyne FM, Franssen MP, Beniers AJ, et al.: New prospects in the management of metastatic renal cell carcinoma. Experimental and clinical data. Prog Clin Biol Res 1990, 350:243–255.

    PubMed  CAS  Google Scholar 

  31. Fisher RI, Coltman CA, Doroshow JH et al.: Metastatic renal cancer treated with interleukin-2 and lymphokineactivated killer cells: a phase II clinical trial. Ann Intern Med 1988, 108:518–523.

    PubMed  CAS  Google Scholar 

  32. Jayson GC, Middleton M, Lee SM, et al.: A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer 1998, 78:366–369.

    PubMed  CAS  Google Scholar 

  33. Elias L, Lew D, Figlin RA, et al.: Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study. Cancer 2000 89:597–603.

    Article  PubMed  CAS  Google Scholar 

  34. Negrier S, Caty A, Lesimple T, et al.: Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d’Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000, 18:4007–4008.

    Google Scholar 

  35. Figlin RA, Thompson JA, Bukowski RM, et al.: Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999, 17:2521–2529.

    PubMed  CAS  Google Scholar 

  36. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnology 1992, 24:524–526.

    PubMed  Google Scholar 

  37. Steinman RM, Young JW: Signals arising from antigenpresenting cells. Curr Opin Immunol 1991, 3:361–372.

    Article  PubMed  CAS  Google Scholar 

  38. Kiertscher S, Roth M: Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukocyte Biol 1996, 59:208–218.

    PubMed  CAS  Google Scholar 

  39. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macropgage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994, 179:1109–1118.

    Article  PubMed  CAS  Google Scholar 

  40. Inaba K, Metlay JP, Crowley MT, et al.: Dendritic cells as antigen presenting cells in vivo. Int Rev Immunol 1990, 6:197–206.

    PubMed  CAS  Google Scholar 

  41. Huang M, Golumbek P, Ahmadzadeh M, et al.: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994, 264:961–965.

    Article  PubMed  CAS  Google Scholar 

  42. Freudenthal PS, Steinman RM: The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci U S A 1990, 87:7698–7702.

    Article  PubMed  CAS  Google Scholar 

  43. Flamand V, Sornasse T, Thielemans K, et al.: Murine dendritic cells pulsed in-vitro with tumor antigens induce tumor resistance in-vivo. Eur J Immunol 1994, 24:605–610.

    Article  PubMed  CAS  Google Scholar 

  44. Mayordomo JI, Zorina T, Storkus WJ, et al.: Bone marrowderived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nature Med 1995, 1:1297–1302.

    Article  PubMed  CAS  Google Scholar 

  45. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996, 2:52–58.

    Article  PubMed  CAS  Google Scholar 

  46. Storkus WJ, Zeh HJ III, Salter RD, Lotze MT: Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 1993, 14:94–103.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology and Medical Oncology, University Hospital St. Radboud, Geert Grooteplein, Box 9101, 6500, HB Nijmegen, the Netherlands

    Peter F. A. Mulders MD & Pieter H. M. de Mulder MD

Authors
  1. Peter F. A. Mulders MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pieter H. M. de Mulder MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mulders, P.F.A., de Mulder, P.H.M. The role of adjuvant immunotherapy in renal cell carcinoma. Curr Urol Rep 3, 44–49 (2002). https://doi.org/10.1007/s11934-002-0010-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-002-0010-y

Keywords

Search

Navigation